United States Next-Generation Sequencing Market Size, Share, Trends, Growth and Forecast Report by Product, Application, Technology, End User, States and Company Analysis 2026–2034

United States Next-Generation Sequencing Market Size and Overview

United States Next-Generation Sequencing Market is expected to witness robust expansion, increasing from US$ 4.62 billion in 2025 to US$ 20.23 billion by 2034, registering a CAGR of 17.83% during 2026–2034. This strong growth is supported by the rapid integration of precision medicine into healthcare, rising demand for genomic testing in oncology and rare disease diagnosis, continuous technological innovations in sequencing platforms, and increasing investments in genomics research by government agencies, academic institutions, and private organizations.

What is Next-Generation Sequencing and Popularity in United States?

Next-Generation Sequencing (NGS) represents a transformative advancement in genomic science, enabling researchers and clinicians to sequence DNA and RNA with exceptional speed, accuracy, and scalability. Unlike conventional sequencing methods that analyze genetic material one fragment at a time, NGS can process millions of sequences simultaneously, delivering comprehensive genomic insights while reducing turnaround time and overall sequencing costs. These capabilities have made NGS an indispensable tool in both clinical diagnostics and biomedical research.

The technology has become a cornerstone of modern healthcare and life sciences, supporting a broad range of applications including cancer genomics, inherited and rare disease diagnosis, infectious disease surveillance, reproductive and prenatal testing, pharmacogenomics, agricultural biotechnology, and drug discovery. As sequencing becomes more affordable and bioinformatics tools continue to improve, NGS is increasingly being adopted for routine clinical use, expanding its role beyond research laboratories into hospitals and diagnostic centers.

United States remains a global leader in the adoption and advancement of Next-Generation Sequencing technologies. A well-established biotechnology ecosystem, world-renowned research institutions, strong federal funding for genomic research, and the presence of leading sequencing technology companies have created an environment that encourages continuous innovation. In addition, the growing emphasis on personalized healthcare, nationwide cancer genomics initiatives, expanding clinical genetic testing, and the integration of genomic data into patient care are accelerating the demand for NGS solutions across the country. As precision medicine continues to evolve, the United States is expected to maintain its leadership position in the global NGS market throughout the forecast period.

U.S. Genetic Testing Awareness and Adoption

• 81% of Americans were aware of genetic testing in 2022, compared with 75% in 2020.
• 40% of Americans reported having undergone at least one genetic test in 2022, a significant increase from 19% in 2020.
• The findings are based on responses from 6,252 participants in the 2022 Health Information National Trends Survey (HINTS) conducted by researchers at the University of Texas Southwestern Medical Center (UTSW).
• Ancestry testing had the highest level of public awareness, with 72% of respondents familiar with it.
• 55% of respondents were aware of genetic testing for specific diseases.
• 37% were aware of prenatal genetic carrier testing.
• 25% reported awareness of genetic testing for personal traits.
• Among the 4,403 respondents who answered questions about genetic test usage, 23% had taken an ancestry genetic test, making it the most commonly used type.
• 16% had undergone genetic testing for specific disease risk.
• 8% reported using prenatal genetic carrier testing.
• 6% had completed personal trait genetic testing.
• The survey highlights the rapid growth in consumer awareness and adoption of genetic testing in the United States between 2020 and 2022, reflecting increasing public acceptance of genomics in healthcare and personal wellness.

Key Growth Drivers

Rising Adoption of Precision Medicine

The increasing shift toward precision medicine is one of the most significant factors accelerating the growth of the United States Next-Generation Sequencing (NGS) market. As healthcare providers move away from generalized treatment approaches, genomic sequencing has become essential for identifying disease-causing mutations, selecting targeted therapies, and predicting patient responses to medications. NGS plays a critical role in oncology, rare genetic disorders, inherited diseases, and pharmacogenomics by providing detailed genetic insights that support individualized treatment decisions. Government-backed precision medicine initiatives, expanding genomic screening programs, and the growing use of companion diagnostics by pharmaceutical companies are further strengthening market demand. As personalized healthcare becomes more deeply integrated into clinical practice, the need for high-throughput, accurate, and cost-efficient sequencing technologies continues to increase across the United States. In November 2025, Precision Medicine Group introduced Institute Precision, a global collaboration platform that brings together scientists, clinicians, regulators, commercial experts, and biopharmaceutical leaders to advance innovation and address complex challenges in precision medicine.

Strong Genomics Research Ecosystem and Investment

The United States maintains a leadership position in genomics research due to its well-developed scientific infrastructure and substantial investments from government organizations, academic institutions, biotechnology companies, and pharmaceutical firms. Continuous funding for genomic research has accelerated discoveries in cancer biology, infectious disease surveillance, population genomics, and translational medicine. These investments have significantly expanded the use of Next-Generation Sequencing across research laboratories, hospitals, and clinical diagnostic centers. Public-private collaborations and ongoing innovation in genomic technologies continue to enhance sequencing capabilities while encouraging broader commercial adoption. Reflecting this momentum, Foundation Medicine announced in February 2025 the launch of FoundationOne Germline and FoundationOne Germline More in the United States, enabling healthcare professionals to identify inherited genetic mutations associated with cancer and improve risk assessment for affected individuals and their families.

Continuous Technological Advancements in Sequencing Platforms

Ongoing technological innovation remains a major catalyst for the expansion of the U.S. Next-Generation Sequencing market. Improvements in sequencing chemistry, automation, artificial intelligence, and bioinformatics software have significantly enhanced sequencing accuracy, shortened processing times, and increased throughput while lowering operational costs. These advancements are making NGS more accessible for clinical diagnostics in addition to research applications. The development of compact benchtop sequencing systems has enabled hospitals, diagnostic laboratories, and regional healthcare facilities to perform genomic testing more efficiently without relying solely on centralized laboratories. Enhanced software platforms capable of faster genomic analysis are also streamlining clinical workflows and improving decision-making. In January 2024, QIAGEN Digital Insights introduced an upgraded CLC Genomics Workbench powered by LightSpeed technology, providing faster genomic data analysis and supporting more efficient research and clinical applications.

Market Challenges

Growing Complexity of Genomic Data Analysis

Despite remarkable technological progress, managing and interpreting the enormous volume of data generated by Next-Generation Sequencing remains a significant challenge. Every sequencing run produces extensive genomic datasets that require sophisticated computational infrastructure, advanced bioinformatics tools, and highly skilled professionals for accurate analysis. Many healthcare institutions, particularly smaller hospitals and independent laboratories, continue to face difficulties related to data storage, integration with electronic health records, and long-term data management. In addition, the shortage of experienced bioinformaticians, molecular geneticists, and genetic counselors limits the efficient interpretation of sequencing results, increasing operational costs and slowing clinical adoption. These challenges remain important barriers to the widespread implementation of NGS technologies across the healthcare sector.

Regulatory and Reimbursement Uncertainties

Regulatory compliance and reimbursement policies continue to present obstacles for companies operating in the U.S. Next-Generation Sequencing market. Although genomic testing is becoming increasingly important in clinical care, approval pathways for new sequencing-based diagnostic tests can be lengthy and complex. Furthermore, reimbursement policies differ considerably among Medicare, Medicaid, and private insurance providers, creating uncertainty regarding coverage and payment for many NGS-based tests. Diagnostic laboratories and healthcare providers often face financial risks when reimbursement decisions are inconsistent or delayed. At the same time, evolving regulatory requirements demand continuous investments in quality assurance, clinical validation, and compliance, increasing development costs and extending the time required to bring innovative sequencing solutions to market.

Next-Generation Sequencing (NGS) Product Launches in the United States

• Illumina MiSeq i100 & MiSeq i100 Plus (October 2024) – Illumina launched its next-generation benchtop sequencing systems featuring room-temperature reagents, faster turnaround times, and simplified workflows for research and clinical laboratories, making NGS more accessible to smaller labs.
• Illumina Complete Long Read Prep, Human (March 2023) – Illumina introduced its first long-read sequencing solution, enabling both long- and short-read sequencing on existing NovaSeq X and NovaSeq 6000 platforms to improve structural variant detection and whole-genome analysis.
• Illumina TruSight Oncology Comprehensive (FDA Approval – August 2024) – The FDA approved Illumina's comprehensive NGS-based companion diagnostic for profiling 517 cancer-related genes, supporting precision oncology and targeted therapy selection in U.S. clinical laboratories.
• PacBio Onso Short-Read Sequencing System (August 2023) – Pacific Biosciences began commercial shipments of the Onso platform, utilizing Sequencing by Binding (SBB) chemistry to deliver exceptionally accurate short-read sequencing for translational research and clinical genomics.
• QIAGEN LightSpeed-Powered CLC Genomics Workbench (January 2024) – QIAGEN Digital Insights released an upgraded CLC Genomics Workbench with LightSpeed technology, significantly accelerating NGS data analysis and improving genomic workflow efficiency for researchers and diagnostic laboratories.
• Foundation Medicine FoundationOne Germline (February 2025) – Foundation Medicine launched the FoundationOne Germline test in the United States, expanding its NGS portfolio with comprehensive germline testing for hereditary cancer risk assessment.
• Foundation Medicine FoundationOne Germline More (February 2025) – Alongside FoundationOne Germline, the company introduced FoundationOne Germline More, offering expanded inherited cancer gene analysis to support personalized clinical decision-making.
• Roche Sequencing by Expansion (SBX) Technology (February 2025) – Roche unveiled its breakthrough Sequencing by Expansion (SBX) platform, a new high-throughput NGS technology designed to reduce sequencing time from days to hours while improving scalability and flexibility for research and clinical applications.
• Roche Axelios Gene Sequencing System (June 2026) – Roche introduced the Axelios sequencing platform in the U.S., leveraging SBX technology to provide high-speed, long-read sequencing and compete with established high-throughput sequencing systems.
• Oxford Nanopore MinION Mk1C (FDA Marketing Authorization – 2025) – Oxford Nanopore's portable MinION Mk1C sequencing system received U.S. FDA marketing authorization, expanding access to real-time genomic sequencing for clinical, public health, and research applications.

Product Analysis

Next-Generation Sequencing Instruments

The United States Next-Generation Sequencing (NGS) instruments market is experiencing strong growth, driven by increasing demand from academic research institutions, clinical laboratories, biotechnology companies, and pharmaceutical organizations. Advanced sequencing platforms, including high-throughput and benchtop systems, are widely used for applications such as cancer genomics, infectious disease surveillance, rare disease research, and whole-genome sequencing. Continuous improvements in sequencing speed, automation, accuracy, and affordability are encouraging laboratories to upgrade their existing platforms, while the introduction of next-generation instruments with enhanced throughput and integrated software is further supporting market expansion.

Next-Generation Sequencing Services

The demand for Next-Generation Sequencing services is expanding rapidly across the United States as many organizations choose outsourcing over investing in expensive sequencing infrastructure. Research institutions, hospitals, biotechnology firms, and pharmaceutical companies increasingly rely on specialized service providers for sample preparation, sequencing, bioinformatics analysis, and interpretation of genomic data. Outsourcing enables organizations to reduce operational costs, access advanced sequencing technologies, and benefit from expert data analysis without significant capital investment. The growing number of clinical research projects, precision medicine programs, and drug development initiatives continues to strengthen the market for NGS service providers.

Application Analysis

Next-Generation Sequencing Diagnostics

The adoption of Next-Generation Sequencing in clinical diagnostics is growing steadily across the United States as healthcare providers increasingly incorporate genomic testing into routine patient care. NGS-based diagnostic solutions are extensively used for cancer profiling, inherited disease detection, prenatal and newborn screening, pharmacogenomic testing, and infectious disease identification. Rising physician awareness, expanding clinical evidence supporting genomic medicine, and the availability of more comprehensive diagnostic panels are accelerating adoption. In addition, improving reimbursement policies for selected genetic tests and growing regulatory acceptance are encouraging healthcare institutions to integrate NGS diagnostics into standard clinical workflows.

Drug Discovery Next-Generation Sequencing

The United States Drug Discovery Next-Generation Sequencing market is expanding rapidly as pharmaceutical and biotechnology companies increasingly utilize genomic technologies to improve research efficiency and accelerate therapeutic development. NGS plays a critical role in identifying novel drug targets, discovering predictive biomarkers, understanding disease mechanisms, supporting pharmacogenomics research, and developing companion diagnostics for precision therapies. By generating comprehensive genomic insights, sequencing technologies help researchers make better-informed decisions throughout preclinical research, clinical trials, and drug commercialization. Strong investment in precision medicine, biologics, and gene-based therapies, combined with the presence of leading biotechnology firms, Contract Research Organizations (CROs), and academic research centers, continues to drive robust market growth.

Technology Analysis

Sequencing by Synthesis (SBS)

Sequencing by Synthesis (SBS) remains the dominant technology in the United States Next-Generation Sequencing market due to its exceptional accuracy, scalability, and broad range of clinical and research applications. The technology is extensively used for whole-genome sequencing, whole-exome sequencing, RNA sequencing, targeted gene analysis, and transcriptomics studies. Its ability to deliver highly reliable results with high throughput has established SBS as the preferred sequencing method across research institutions, diagnostic laboratories, and healthcare organizations. Continuous advancements in sequencing chemistry, automation, instrument performance, and bioinformatics software have further improved workflow efficiency while reducing sequencing costs, reinforcing the technology’s leadership position in the U.S. market.

Ion Semiconductor Sequencing

Ion semiconductor sequencing represents an important and steadily growing segment of the U.S. Next-Generation Sequencing market, particularly for applications requiring rapid and targeted genomic analysis. Unlike optical sequencing methods, this technology detects hydrogen ions released during DNA synthesis, enabling faster sequencing with simplified instrument design and reduced operational complexity. These advantages make ion semiconductor sequencing particularly suitable for hospital laboratories, regional diagnostic centers, oncology testing, infectious disease diagnostics, and targeted gene panels where rapid turnaround times are essential. Although its market share remains smaller than Sequencing by Synthesis, continuous technological improvements and expanding clinical applications are supporting sustained growth across the United States.

End User Analysis

Next-Generation Sequencing Hospitals and Clinics

Hospitals and clinics are emerging as one of the fastest-growing end-user segments within the United States Next-Generation Sequencing market as genomic medicine becomes increasingly integrated into routine healthcare. Healthcare providers are adopting NGS technologies for cancer diagnosis, rare genetic disorder identification, prenatal and newborn screening, infectious disease management, and personalized treatment planning. Many hospitals are investing in in-house sequencing capabilities, while others continue to collaborate with specialized genomic laboratories to meet rising testing demand. The availability of compact benchtop sequencing systems, automated laboratory workflows, improved clinical decision-support tools, and expanding reimbursement for selected genomic tests is making NGS more accessible across healthcare settings. As precision medicine continues to gain momentum, hospitals and clinics are expected to remain a major contributor to the long-term growth of the U.S. Next-Generation Sequencing market.

States Analysis

California Next-Generation Sequencing

California remains the largest and most technologically advanced regional market for Next-Generation Sequencing (NGS) in the United States, supported by its globally recognized biotechnology ecosystem and extensive genomics research infrastructure. The state is home to leading biotechnology companies, world-class universities, academic medical centers, and genomic research institutes, particularly in innovation hubs such as the San Francisco Bay Area and San Diego. Strong venture capital funding, substantial government research grants, and continuous investment in life sciences have accelerated the adoption of NGS across precision medicine, oncology, rare disease diagnostics, infectious disease research, and pharmaceutical development. In addition, hospitals and clinical laboratories throughout California are increasingly integrating genomic sequencing into routine clinical practice, reinforcing the state’s leadership in advancing personalized healthcare and genomic innovation.

New York Next-Generation Sequencing

New York has established itself as a major center for Next-Generation Sequencing adoption, driven by its highly developed healthcare infrastructure, prestigious academic institutions, and internationally recognized medical research centers. The state’s leading hospitals and research organizations actively utilize NGS technologies for precision oncology, translational medicine, pharmacogenomics, and population health studies. Access to diverse patient populations supports large-scale genomic research and enables the development of more personalized treatment strategies. Furthermore, increasing implementation of genomic testing for cancer diagnosis, prenatal screening, inherited disorders, and rare disease identification continues to expand the clinical use of NGS throughout New York’s healthcare system.

New Jersey Next-Generation Sequencing

New Jersey plays a vital role in the U.S. Next-Generation Sequencing market due to its strong concentration of pharmaceutical manufacturers, biotechnology companies, and life sciences organizations. The state’s close proximity to major research institutions and healthcare networks across the Northeast fosters collaboration in genomic research, clinical development, and precision medicine initiatives. NGS technologies are widely employed in drug discovery, biomarker identification, companion diagnostic development, clinical trials, and translational research. Growing adoption among hospitals, diagnostic laboratories, and biotechnology companies for cancer genomics, inherited disease testing, and molecular diagnostics continues to strengthen the regional market. In addition, the presence of regulatory expertise and a mature life sciences ecosystem supports ongoing technological innovation and commercialization.

Texas Next-Generation Sequencing

Texas has emerged as one of the fastest-growing markets for Next-Generation Sequencing in the United States, supported by rapid population growth, expanding healthcare infrastructure, and increasing demand for advanced genomic diagnostics. Major metropolitan areas such as Houston, Dallas, and Austin host leading medical centers, biotechnology companies, research institutions, and genomic laboratories that are actively advancing the adoption of sequencing technologies. Rising investments in biotechnology, precision medicine, and genomic research have accelerated the use of NGS for cancer genomics, infectious disease surveillance, inherited disease diagnosis, and biomedical research. As healthcare providers continue to incorporate genomic testing into clinical practice, Texas is expected to remain a key contributor to the long-term expansion of the U.S. Next-Generation Sequencing market.

Market Segmentations

Product

• Instruments
• Reagents & Consumables
• Services

Application

• Diagnostics
• Agriculture and Animal Research
• Drug Discovery
• Personalized Medicine and Genetic Screening
• Others

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single Molecule Read Time Sequencing
• Nanopore Sequencing
• Others

End User

• Academic and Clinical Research Centers
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Others

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• QIAGEN N.V
• Roche
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• Hamilton Company
• Geneious
• BioMérieux SA

Report Details: